Funding news · Nov 17, 2026

AstraNu Raises $3.5M Seed Led by Celesta Capital for Chip-Scale OCT Imaging Engine

AstraNu Closes $3.5M Seed Round

AstraNu, a Nokia Bell Labs spinout based in Murray Hill, New Jersey, has raised a $3.5 million seed round. The round was led by Celesta Capital, with participation from the New Jersey Innovation Evergreen Fund. The funding date is November 17, 2026.

What AstraNu Does

AstraNu is developing a chip-scale optical coherence tomography (OCT) imaging engine for the medical device industry. The company applies telecom photonics know-how to deliver swept-source OCT performance at spectral-domain price points.

Key characteristics of the platform, as described by the company:

  • A module more than 10x smaller than conventional swept-source systems
  • Significantly lower cost than conventional swept-source systems
  • Swept-source OCT performance delivered at spectral-domain price points

Business Model and Market Focus

AstraNu supplies its imaging engine to medical device, imaging and optics companies for integration into their own products. It does not appear to sell a finished clinical system directly; instead, it positions itself as a component and engine supplier to OEMs.

Ophthalmology is the initial commercial focus. The company also has applications in development across ENT (ear, nose and throat), urology and oncology.

Why the Spinout Matters

The company's origin at Nokia Bell Labs is notable. AstraNu is translating telecom photonics capabilities into the medical imaging space, aiming to bring the performance advantages of swept-source OCT into smaller, lower-cost modules that device makers can embed in their products.

Round Summary

  • Company: AstraNu
  • Headquarters: Murray Hill, New Jersey
  • Stage: Seed
  • Amount: $3.5 million
  • Currency: USD
  • Funding date: November 17, 2026
  • Lead investor: Celesta Capital
  • Additional investor: New Jersey Innovation Evergreen Fund

Acquisition Perspective

For strategic buyers in medical devices, imaging and optics, AstraNu represents an early-stage component play. Its value proposition rests on module size and cost relative to conventional swept-source OCT systems, combined with a supplier model that places its engine inside partners' products. The seed round provides capital to advance the platform, with ophthalmology as the first commercial target and additional clinical applications in development.

© 2026 VeilStrat. All rights reserved.All systems operational